Symbio Pharmaceuticals Limited (4582) AI Stock Analysis

• Market Cap: ¥5.41B
• Dividend Yield: N/A
• Average Volume (3M): 577.10K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: -50.27%
• EPS Growth: -3.33%
• Country: JP
• Employees: 108
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -24.11
• Shares Outstanding: 59,561,930
• 10 Day Avg. Volume: 434,010
• 30 Day Avg. Volume: 577,100
• PEG Ratio: -0.03
• Price to Book (P/B): 2.14
• Price to Sales (P/S): 3.66
• P/FCF Ratio: -2.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: ¥87.00 ▼(-3.33% Downside)

The score is held down primarily by worsening profitability and cash burn, alongside a clearly bearish technical trend. A debt-free balance sheet provides some risk mitigation, but valuation metrics offer limited support given ongoing losses and no dividend data.

Positive Factors

Debt-Free Balance Sheet

A debt-free balance sheet reduces financial risk and provides flexibility, allowing the company to navigate financial challenges without the burden of interest payments.

Strong Gross Margins

Maintaining strong gross margins indicates efficient cost management in production, which can support profitability as revenue stabilizes or grows.

Focus on Oncology and Hematology

Specialization in oncology and hematology positions the company in high-demand therapeutic areas, potentially driving long-term growth as these markets expand.

Negative Factors

Deteriorating Financial Performance

Worsening financial performance with renewed losses and negative cash flow indicates operational challenges that could impact long-term viability if unaddressed.

Significant Revenue Decline

A sharp decline in revenue reflects market challenges or competitive pressures, which could hinder growth prospects and require strategic realignment.

Equity Pressure from Losses

Continued losses erode equity, reducing financial stability and potentially limiting the company's ability to invest in growth opportunities.

Symbio Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.

How the Company Makes Money

Symbio Pharmaceuticals Limited generates revenue through multiple streams, primarily by manufacturing and selling pharmaceutical products. The company's core revenue comes from the sale of its proprietary prescription drugs and over-the-counter medications to healthcare providers, pharmacies, and direct consumers. Symbio also engages in licensing agreements and strategic partnerships with other pharmaceutical companies, leveraging its research and development capabilities to co-develop new medications and treatments. Additionally, the company may receive milestone payments and royalties from these partnerships, further contributing to its income. By consistently investing in research and development, Symbio Pharmaceuticals ensures a steady pipeline of innovative products that drive its growth and profitability.

Symbio Pharmaceuticals Limited Financial Statement Overview

Summary

Symbio Pharmaceuticals is navigating a challenging period with declining revenues and significant losses impacting profitability and cash flow. The company maintains a strong equity position with no debt, which could support future recovery. However, strategic improvements in revenue generation and cost management are essential for financial stability.

Income Statement

Symbio Pharmaceuticals has faced significant challenges, with revenues declining from 2022 to 2024. The company has been operating at a loss with negative EBIT and EBITDA margins, and a substantial decrease in net income. The gross profit margin remains reasonable, but overall profitability is severely impacted by high operating losses.

Balance Sheet

The company maintains a strong equity position with no debt, reflected in a debt-to-equity ratio of zero. However, the return on equity has been negative due to sustained net losses. The equity ratio is healthy, indicating a solid capital structure despite financial losses.

Cash Flow

Symbio Pharmaceuticals has experienced negative free cash flow growth, consistent with operating losses. Operating cash flow has been negative, indicating cash flow challenges. Free cash flow to net income ratios are also negative, highlighting the need for cash management improvements.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.82B	2.45B	5.59B	10.01B	8.25B	2.99B
Gross Profit	1.37B	1.87B	4.41B	7.60B	5.80B	866.85M
EBITDA	-4.61B	-3.78B	-714.00M	2.06B	1.11B	-4.44B
Net Income	-4.66B	-3.83B	-1.96B	1.18B	2.03B	-4.09B
Balance Sheet
Total Assets	4.14B	4.97B	8.17B	10.43B	8.45B	6.27B
Cash, Cash Equivalents and Short-Term Investments	3.05B	3.96B	6.52B	6.28B	3.86B	3.85B
Total Debt	1.30B	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.78B	770.77M	960.33M	1.93B	1.71B	1.62B
Stockholders Equity	2.36B	4.20B	7.21B	8.51B	6.75B	4.66B
Cash Flow
Free Cash Flow	0.00	-3.44B	-427.48M	1.57B	76.20M	-4.27B
Operating Cash Flow	0.00	-3.42B	-194.69M	1.61B	140.04M	-4.12B
Investing Cash Flow	0.00	-3.96M	-376.70M	-47.13M	-70.85M	-160.31M
Financing Cash Flow	0.00	708.47M	680.16M	627.99M	-71.92M	4.22B

Symbio Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 90.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4582, the sentiment is Negative. The current price of 90 is below the 20-day moving average (MA) of 91.55, below the 50-day MA of 100.58, and below the 200-day MA of 142.02, indicating a bearish trend. The MACD of -3.28 indicates Negative momentum. The RSI at 35.59 is Neutral, neither overbought nor oversold. The STOCH value of 52.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4582.

Symbio Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4524	65 Neutral	¥8.97B	15.49	―	2.55%	3.23%	42.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4892	49 Neutral	¥5.78B	-6.01	―	―	56.17%	-11.63%
4586	44 Neutral	¥7.01B	-4.64	―	―	-52.41%	-80.31%
4597	43 Neutral	¥7.79B	-3.58	-90.96%	―	243.16%	-23.00%
4582	42 Neutral	¥5.41B	-0.96	―	―	-50.27%	-3.33%
4883	42 Neutral	¥5.29B	-2.21	―	―	―	47.43%

Symbio Pharmaceuticals Limited Corporate Events

SymBio Pharmaceuticals Reports Significant Financial Decline in 2025

SymBio Pharmaceuticals Limited reported a significant decline in financial performance for the first nine months of fiscal year 2025, with net sales dropping by 48.9% compared to the previous year. The company experienced substantial operating and ordinary losses, reflecting ongoing financial challenges. The equity ratio also decreased significantly, indicating a weakened financial position. The forecast for the full fiscal year 2025 suggests continued financial difficulties, with expected declines in net sales and further losses, signaling potential concerns for stakeholders and the need for strategic adjustments.